• WHO director-general warns COVID-19 is “most certainly not over”
• KNOS building reputation for effective, advanced, state-of-the-art air filtration and purification systems
• Company also offers Kronos(R)-designed graphene N95 face masks made in U.S. at NIOSH-certified facility

While mask mandates have been lifted and life appears to be returning to normal in many places around the world, the COVID-19 pandemic is “most certainly not over,” reported Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (https://ibn.fm/8YfkT). The need for continued vigilance has spurred many companies, including Kronos Advanced Technologies (OTC: KNOS), that are working to provide people with protection against the deadly virus and its variants. The warning came, reported U.S. News & World Report, “despite a decline in reported cases since the peak of the omicron wave. [Tedros] told governments that ‘we lower our guard at our peril.’” The report noted that the head of WHO, while opening the organization’s annual meeting in Geneva, said “that ‘declining testing and sequencing means we are blinding ourselves to the evolution of the virus.’ He also noted that almost 1 billion people in lower-income countries still haven’t been vaccinated.” In a weekly report on the global situation, “WHO said the number of new COVID-19 cases appears to have stabilized after weeks of decline since late March, while the overall number of weekly deaths dropped,” the article continued. “While there has been progress, with 60% of the world’s population vaccinated, ‘it’s not over anywhere until it’s over everywhere,’ Tedros said. ‘Reported cases are increasing in almost 70 countries in all regions, and this in a world in which testing rates have plummeted.’” Kronos Advanced Technologies has built a reputation for offering some of the most effective, advanced, state-of-the-art air filtration and purification systems available. The proprietary Kronos(R) systems fully remove harmful allergens, bacteria, viruses (including the flu) and even gasses from indoor breathing spaces, including healthcare and other settings. In addition to air filtration systems, Kronos also offers Kronos(R)-designed graphene N95-compatible face masks made in the United States at a NIOSH-certified facility (https://ibn.fm/vaA5J). Kronos recently announced test results from Nelson Labs demonstrating significantly enhanced bacterial filtration efficiency (“BFE”) and viral filtration efficiency (“VFE”). According to the update, Kronos’ designed and U.S.-manufactured 5-ply graphene face masks remove 99.9% of bacteria and virus particles, compared to the common and far less efficacious ASTM level 3 mask. The company believes that, with BFE and VFE levels over 99.9%, these are the highest filtration efficiency numbers for any face masks in the market. “Our goal is to provide the best available protective face masks on the market for those in higher-exposure risk environments, with the best technology available,” said Kronos CEO Michael Rubinov (https://ibn.fm/A1xB2). “Our Kronos graphene technology achieves this not only as of the highest protection properties but also by completely reducing the number of viable bacteria and virus particles that are able to pass through the mask materials to zero.” Kronos’ patented medical-grade technology is tested as the most-effective, clean-air solution on the market. Kronos filters particles down to .0146 micron (.0146μm), much smaller than the 3 microns (0.3μm) of a traditional HEPA filter. Kronos not only collects but destroys air pollutants; the company’s Kronos AIR 5G(R) Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles. The Kronos face mask is the only five-ply graphene mask made in the United States. Kronos Advanced Technologies is exploring broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices, including schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and automobiles and commercial aircraft cabins. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

 

• Corporate issuers are spending over $675,000 annually on climate-related disclosures
• Institutional investors, on the other hand, spend about $1.4 million to collect, analyze and report climate data
• Correlate Infrastructure Partners Inc. seeks to offer deep financial savings and energy efficiency by reducing site-specific energy consumption and deploying clean energy generation
• Through its offering, it aims to help companies and investors cut down on costs associated with climate-related disclosures while also helping them adhere to the new rules and guidelines

Companies worldwide are facing increasing pressure to provide climate-related disclosures. Regulators have been at the forefront of demanding these releases in a move that seeks to foster accountability and push for a more sustainable and greener planet. Most notably, the United States Securities Exchange Commission (“SEC”) has been on an aggressive push for these disclosures, even unveiling its proposed rules back in March 2022 (https://ibn.fm/hihTE). It is estimated that corporate issuers are spending over $675,000 annually on climate-related disclosures. In addition, it is estimated that institutional investors are spending close to $1.4 million to collect, analyze and report climate data, which is a hefty sum that can be channeled towards other areas of operation, including, but not limited to renewable energy. Correlate Infrastructure Partners (OTCQB: CIPI) has proven to offer deep financial savings and energy efficiency across the commercial sector. With an opportunity pipeline of over $100 million in commercial projects and more than $20 million in awarded backlog, this company seeks to leverage the U.S. portfolio energy optimization market, which is currently valued at $290 billion. In a study conducted by the SustainAbility Institute by ERM, it was discovered that corporate issuers spend over $677,000 every year on climate-related disclosure activities. Greenhouse gas (“GHG”) analysis accounted for the highest expenditure at $237,000 on average, while climate scenario analysis accounted for $154,000. In addition, climate risk management control costs $148,000 on average, which, in total, was not far off from the SEC’s estimates which stood at $640,000. The study, which involved 39 corporate issuers across multiple U.S. sectors, with a market cap range of under $1 billion to over $200 billion, along with 35 institutional investors representing a total of $7.2 trillion of assets under management (“AUM”) was aimed at highlighting the costs incurred by enterprises in the quest for environmental accountability. “This survey shows that both companies and investors recognize the benefits of disclosing their climate-related activities,” noted Mark Lee, the Director of SustainAbility Institute by ERM. “It also offers a rare glimpse into issuer and investors’ current investments in measurement, analysis, and disclosure of climate-related information, which will be a valuable resource for organizations considering their response to the proposed SEC rules,” he added. With this push by the SEC, companies and investors are being urged to adopt greener energy alternatives and lower their overall carbon footprint. Correlate Infrastructure Partners is well-positioned to satisfy this growing need. With its unique value proposition, companies are bound to reap the benefits of its infrastructure, ranging from cost savings to lower carbon emissions and meeting the changing regulations being implemented with every passing day. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM)
• Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”)
• Lexaria is consistently enhancing the delivery of APIs that affect current oral formulations: speed of onset, limited absorption, and low membrane permeability
• Lexaria has conducted numerous ground-breaking studies, some of which open up the possibility of fast-acting oral products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking

Oral formulations account for approximately 90% of the global share of all pharmaceutical formulations made for human use. Statistics also show that about 60% of all established, commercially available small-molecule drug products today and approximately 84% of all best-selling pharmaceutical products are orally administered. Oral drug administration is preferred because it offers numerous advantages over other delivery methods (for instance, intramuscular, subcutaneous, intravenous, and inhalation), not the least of which is high compliance of patients. Additionally, the drugs can be used to offer localized treatment of affected regions within the gastrointestinal tract. “Despite these advantages, the development of oral formulations presents several challenges, which are mainly attributed to the physicochemical properties of drugs, including poor water solubility and membrane permeability. In addition, the absorption of drugs can be limited by their poor chemical and biological stability, as well as by physiological barriers, including pH, efflux transporters, and metabolic enzymes,” reads a 2021 review article published in the Frontiers in Pharmacology Journal (https://ibn.fm/Fj0TC). In understanding the shortcomings of orally administered drugs, Lexaria is rising to the occasion, developing a drug delivery technology that solves the aforementioned challenges. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed DehydraTECH(TM), a patented technology which enhances the efficiency and speed of orally-administered fat-soluble active pharmaceutical ingredients (“API”). “DehydraTECH combines lipophilic APIs with specific fatty acid and carrier compounds, thereby improving the way APIs enter the bloodstream while increasing the effectiveness of fat-soluble active molecules allowing lowering overall dosing and promoting healthier oral ingestion methods,” Lexaria explained in its 2021 annual report (https://ibn.fm/W2hsW). The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications. Now, Lexaria’s website notes, the technology “can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages, and topical preparations.” Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of APIs. So far, Lexaria has explored how DehydraTECH improves APIs, not limited to, cannabidiol (“CBD”), oral nicotine, and antiviral drugs, with the company describing its oral nicotine investigations as “ground-breaking studies to open doors previously closed to disruptive new technology, including the possibility of potent and fast-acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking” (https://ibn.fm/ysLHG). In a series of animal studies staggered between 2018 and 2021, Lexaria evidenced that DehydraTECH delivered considerable nicotine absorption performance improvements compared to controls. The technology resulted in faster delivery of the compound, a higher quantity of peak nicotine delivered to the bloodstream, greater bioavailability, and higher brain absorption (as evidenced by high levels of nicotine in the brain). In its latest animal study, whose results the company released last year, Lexaria revealed that DehydraTECH was between 10x to 20x faster in achieving peak delivery of oral nicotine to the bloodstream than controls. It also attained peak nicotine levels that were up to 10x higher than controls (https://ibn.fm/uBCLc). Now, Lexaria is focusing on the human nicotine study, NIC-H22-1, with dosing expected to begin this summer. The company hopes that the use of DehydraTECH-nicotine pouches –will help avoid harmful outcomes associated with smoking tobacco, a source of nicotine. Tobacco use causes 480,000 deaths (including passive smokers) annually in the United States (https://ibn.fm/dbT1L). Globally, tobacco claims over 8 million lives every year, 7 million of which result from direct tobacco use, while about 1.2 million are caused by the inhalation of secondhand smoke (https://ibn.fm/ZM7lE). In its quest to promoting healthier alternatives to traditional orally administered drugs as well as morbidity-causing practices such as smoking, Lexaria is simultaneously tapping into multibillion-dollar industries. Valued at an estimated $5.9 billion in 2022, the global nicotine pouches market is projected to grow at a CAGR of 31% to reach $29.6 billion by 2028 (https://ibn.fm/krqIF). Similarly, the oral drug delivery market, which was valued at $100.05 billion in 2018, is projected to grow at a CAGR of 6.99% to reach $150.06 billion by 2024 (https://ibn.fm/wTcW1). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Life science companies and professionals are invited to attend Dynamic Global Events’ (“DGE”) 2nd KOL Engagement Forum, livestreaming June 1-2, 2022. A pioneer in organizing networking events, Dynamic Global Events focuses on delivering high-quality data and networking avenues to the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The forum is designed for medical and life science professionals to create strong networking ties and cultivate strong long-term relationships with the most influential thought leaders in the industry. In these uncertain times when there is growing distrust for institutions, these respected partnerships will foster confidence and lend credibility to the products. KOLs are expected to play a significant role in each stage of the drug cycle. The event timings for both days is 9:15am to 3:15pm. The 2-day event will witness speeches, keynotes, and discussions from leading industry life science professionals on how to build a trusted alliance with KOLs. The 2nd KOL Engagement Forum offers this unique opportunity to young and aspiring pharmaceutical, biotech, and medical device professionals to engage with KOLs. This event is designed for life science companies in the wake of the changing scenario where regulations become more strict, the demand for personalized medical products and treatment is growing, and so is the need for better connections with KOLs as well as new thought leaders. Key Reasons to Attend:

• Panel discussions, keynotes, and fireside chats on KOL engagement in virtual and hybrid environments
• Learn and understand the novel techniques of dividing up MSL territories
• Avail of the cross-functional engagement plan and align with the team members to deliver the best experience
• Recognize the most important metrics – and develop new ones
• Build long-term strong networking ties through emotional intelligence
• Build high-performance teams in a hybrid environment
• Reliable strategies for identifying and overcoming the biggest outreach hurdles

The introduction will be given by the Chairperson Bryan N. Bischel, PhD. Field Director, MSLs, East Region Eye Care at AbbVie. With more than 15 years of progressively responsible medical affairs experience, Bryan is an accomplished senior medical affairs professional. He is a strategic thinker and a thought leader with high-performance skills to hire, train, and direct high-impact MSL teams. To learn more, please visit https://ibn.fm/TZnZR.

The Social Media & Influencer Strategies Summit promises to bridge the “best of both worlds,” conflating two conferences set to be held over four days. Organized by GSMI Events, the virtual event scheduled for June 7-10 includes a two-day Social Media Summit set for June 7 and 8, in which the speakers and panelists will focus their talks on social media marketing and content strategy, and an Influencer Summit subsequently slated for June 9 and 10. The latter will feature influencer-marketing-focused case studies and talks delivered by leading figures in the influencer segment. Attendees will get to hear from 50 speakers drawn from leading brands, who will share their proven social media and influencer marketing strategies. Their presentations, panel discussions, and case studies are designed to assist those in attendance to:

• Understand all the attributes of a successful social media strategy that positions a brand for success
• Maximize the performance of their social media and influencer marketing programs
• Probe and audit their current social media initiatives
• Experience and see what is driving success at various companies and inspire innovation as a result
• Enrich their arsenal of tools, resources, and connections to keep their brand at the leading edge of the ever-changing trends in the social media and influencer spaces
• Learn how to tap into the right influencers for their brand, create long-term collaborative relationships, and assess the impact of campaigns on their broader business objectives

Kickoff The Social Media Summit will kick off on June 7 with a panel discussion entitled “Learning to take creative risks to find success on social,” with inputs from Markeia McCarty – Marketing Manager at Hunters Entertainment, Glenn Woods – a Senior Social Media Manager working with Hulu, and Christina Kelleher – the Head of Social Media at Wayfair. This panel discussion will kickstart a day of presentations exploring the best practices for brand’s TikTok strategy and building a data-driven social media strategy, as well as topics such as creating a seamless omnichannel experience, how brands leverage cultural moments for brand awareness, and more. Day 2 The second day will feature two panel discussions as well as presentations exploring how to track and report ROI to reflect social’s business impact, reaching audiences with engaging, on-brand videos, how to define brand identities, the role of community in authentic brand storytelling, and more. Day 3 & 4 The third and fourth days of the event – the first and second days for the Influencer Summit – will include talks and case studies from speakers working with leading brands and agencies in the influencer space. Included in the agenda are topics such as how to integrate shoppable content in influencer marketing campaigns, setting up campaigns for success, integrating influencer marketing into a larger marketing mix (panel discussion), and how to enhance influencer effectiveness with language and visual choices, just to mention a few. Interspersed between the various presentations are breaks meant to facilitate networking and interactions with vendor speakers, and GSMI has designed its virtual event platform around this. The platform will feature an exhibit hall, session rooms, and a portal specifically meant to enable attendees to chat directly with other attendees and set up 1:1 meetings. In addition to the presentations, GSMI Events will make available on-demand sessions, offering visitors and attendees access to talks whenever and wherever they want. These never-before-seen video sessions will cover unique topics, providing new insights even to those who will attend the four-day summit. To learn more, please visit https://socialmediastrategiessummit.com/virtual-conference-june-2022/

The Cannabis World Congress & Business Exposition (CWCBExpo) will be held between June 2-4, 2022, at the Javits Convention Center, Hall 3A, in New York City. Industry heavyweights, the foremost innovators, and pioneering thought leaders will take the stage to discuss emerging trends in cannabis, hemp, and allied sectors. The expo will provide a high-quality business-focused attendee base located in the premier East Coast US cannabis and hemp market. The three-day event will feature an Inside the Industry: Thought Leadership Series in an interactive “Talk Show” format. Co-hosts will include Carl Cameron, veteran journalist and former FOX News reporter; Faye Coleman, Founder and CEO of Pure Genesis, cannabis pioneer and entrepreneur Calvin Frye, and Gretchen Gailey, Chief Strategist at CWCBExpo. The Thought Leadership series will address distinct aspects of the sector each day. Day 1, Thursday, will focus on Investing and Industry Progress, Day 2 will address Policy and Legislation, and Day 3 will explore new developments in Cannabis and Lifestyle. The sessions will be educational and relevant to both the local landscape and the national outlook. The conference program will also feature two keynote conversations with Chris Beals, CEO of Weedmaps, along with Mona Zhang, States Cannabis Policy Reporter, POLITICO, on Thursday, Jun 2; and with Nick Kovacevich, CEO of Greenlane Holdings, along with Tim Seymour, Co-host, CNBC Fast Money. In addition to the wide array of expert speakers and eminent business people in attendance, the summit will host hundreds of exhibitors showcasing cutting-edge product innovations and the latest services. The event shall also host a Networking Mixer on Thursday, June 2, from 5 – 7 pm, sponsored by Weedmaps, so that attendees can network or relax ahead of the second day of the conference. On Friday, June 3, from 6 – 10 pm, CWCBExpo will host the Industry Yacht Party, where attendees can eat, drink and dance with their peers while savoring the majestic New York City skyline. This is a premier networking and deal-making opportunity. To attend either or both events, registered attendees must purchase a Networking Mixer Ticket or an Industry Yacht Party Ticket. Get your tickets now at the best price! Why wait? Cannabis Week, anchored by CWCBExpo, will take place from Monday, May 30 to Sunday, June 5, 2022, and will foster collaboration between the entire cannabis industry through industry deep dives, networking events, and lead-generation opportunities.  Several events will take place during the week throughout New York City. To learn more about Cannabis Week, event itineraries, available offers, and discounts, visit  https://cwcbexpo.com/cannabis-week For more information about the CWCBExpo, please visit https://cwcbexpo.com/

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long, strange trip. Used for millennia in spiritual quests, associated with hippies and currently outlawed by the US Government (though legal in Oregon and decriminalized in various cities and states), Silo Pharma still believes in these medicinal mushrooms. But why? The National Center for Biotechnology Information (at The National Library of Medicine), offers answers:

• In addition to the known recreational, spiritual, and religious uses of magic mushrooms, there is significant medicinal value, as evidenced by anecdotal reports and scientific studies.
• With the increase in the rate of mental disorders globally, now exacerbated by COVID-19, psychedelic-assisted psychotherapies, particularly psilocybin-assisted psychotherapies, may alleviate some of the challenges that face conventional psychiatric medicine.
• To date, over 27,000 scientific articles have been published on psychedelic drugs, with over 1000 particularly on psilocybin. Currently, psilocybin is the most studied psychedelic.
• Of all psychedelic drugs, psilocybin is reported to have the most favorable safety profile…the vast evidence-based data that exist for psilocybin alone suggest that psilocybin may be the most efficacious psychedelic drug for treating [numerous] disorders…
• In addition to having the potential to treat mood and anxiety disorders, psilocybin has also demonstrated analgesic effects as evidenced by numerous clinical studies on the treatment of cluster (“suicide”) headaches, intractable phantom-limb pain (“PLP”), and chronic pain. … In some cases, psilocybin was comparable to or more efficacious than traditional medications such as opioid analgesics…
• Globally, the psychedelic therapeutic market is predicted to reach a valuation of $6.8 billion by 2027, from USD 2 billion in 2019, at a growth rate of 16.3%. The neurogenic market including mental health drugs, therapeutic services, neurodegeneration drugs and cognitive enhancement was valued at USD 373 billion.

Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021;26(10):2948. Published 2021 May 15. doi:10.3390/molecules26102948 Psilocybin’s potential in combating neuroinflammation could change medicine as currently practiced, particularly regarding dementia and CNS disorders. According to “Psychedelics for Brain Injury: A Mini-Review,” neuroinflammatory states occur with diseases such as Alzheimer’s, and Parkinson’s. “There are currently three main classes of anti-inflammatory drugs: non-steroidal anti-inflammatory drugs (NSAIDs), steroids such as prednisone, and biologics which act like sponges to “soak up” inflammatory cytokines. Psychedelics may represent a fourth class of anti-inflammatory drug.” Eric Weisblum, Silo’s CEO, said, “Successful dosing and collection of blood samples from enrolled [TrPR] patients is an important milestone that demonstrates the progress being made … to examine the effects of psilocybin as an anti-inflammatory agent.” Silo’s commitment to psilocybin and anti-inflammatory research includes:

• Executing an option agreement with the University of Maryland, Baltimore studying novel system-homing peptides that could potentially “home to the inflamed CNS [central nervous system] and can differentiate between diseased and healthy CNS tissue.” This could be highly beneficial to multiple sclerosis (“MS”) patients as current treatments are “… given orally or parenterally and their use is associated with various side effects … a specific CNS-homing peptide would enhance the efficacy of the treatment and help limit the side effects significantly.(1) According to Silo, “These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.”
• Collaborating with the University of California San Francisco (“UCSF”) to study the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder, and chronic back pain. Weisblum says, “Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder.  Psilocybin and related compounds have shown strong anti-inflammatory effects in non-human animals, raising the possibility that reducing inflammation is a possible mechanism underlying psilocybin’s positive treatment effects in multiple disorders…”
• Teaming with the University of Maryland, Baltimore, for patented Homing Peptides to target Rheumatoid Arthritis. According to a Silo news release, “The ability … to target inflamed endothelium suggests [homing peptides] could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

(1) Acharya, Bodhraj et al. “A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.” Molecular and cellular probes vol. 51 (2020): 101530. doi:10.1016/j.mcp.2020.101530 For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• J.D. Power survey reports range was factor most cited in deciding what EV to buy
• Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space
• Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies

One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 Energy.gov study reported that the median rage for EV last year was 234 miles (https://ibn.fm/tvIzU). Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, is focused on improving that number; the company is currently actively testing advanced battery technology which can provide a range of 600-plus miles on a full charge at the pack level (https://ibn.fm/4H957). “When modern all-electric vehicles (‘EV’) were introduced in model year (‘MY’) 2011, there were four models available with ranges spanning from 63 to 94 miles with a median range of 68 miles,” reports Energy.gov. “Over time, the number of models and the ranges of EVs have increased. By MY 2021, the maximum range for an EV had more than quadrupled to 405 miles on a single charge, while the median range was 234.” This range limitation is causing concern for consumers. Forbes Wheel reports that in a 2021 J.D. Power survey, range was the factor most cited in deciding what EV to buy (https://ibn.fm/qx4Yy), and a ScienceABC article noted that more than 80% of consumers were hesitant to buy an electric vehicle because of range anxiety, along with the higher purchase cost (https://ibn.fm/cl3Om). “We have grown accustomed to conventional internal combustion engine (‘ICE’) vehicles for more than a century,” the article states. “Thus, there is a robust network of gas stations in most countries. In the US, an average American is just four minutes away from a gas station. Meanwhile, an average American lives 30 minutes away, on average, from a Tesla charging station. Tesla accounts for nearly 80% of electric car sales in the US, so looking at the statistics, the development of range anxiety is unsurprising.” Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space, thereby alleviating range anxiety for potential EV buyers. Earlier this year, the company announced an update on its next-generation solid-state polymer battery technology, which is a significant advancement over today’s current lithium-ion batteries. “Mullen’s testing of solid-state polymer cells reveals the potential for a 150-kilowatt-hour battery pack that delivers over 600-plus miles of range and highlights an 18-minute DC fast charge which can yield over 300 miles of range,” the announcement says. “Mullen is working towards utilizing solid-state polymer battery packs in its second-generation Mullen FIVE EV Crossovers, with in-vehicle prototype testing set for 2025.” Recognizing the importance of battery and range in the success of an EV, Mullen is also exploring other advanced battery technologies, including lithium-sulfur and lithium-iron-phosphate. The company is committed to do whatever is necessary to deliver EV batteries that will surpass today’s existing lithium-ion technology and offer a host of benefits, such as increased efficiency, energy density, and range, while also lowering the cost, weight, thermal and environmental risks. “We’ve conducted successful testing and will begin pack level development next,” states Mullen CEO and chair David Michery. “The test data collected shows an impressive outcome and future for solid-state batteries. To sum up, we tested our 300 Ah (ampere-hour) cell, which yielded 343 Ah at 4.3 volts, and the results surpassed all expectations. We can say with almost certainty that this technology, once implemented on the Mullen FIVE, will deliver over 600 miles of range on a full charge. The future is bright for Mullen Automotive.” Mullen is a Southern Californian automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
• CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
• Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology (https://ibn.fm/1vach). “In our national survey on mental health and coronavirus, we found that the COVID-19 pandemic has affected the mental health of 59% of people in the United States,” reported a recent SingleCare article (https://ibn.fm/IBtft). “Dismantling the stigma around mental illness is important now more than ever.” SingleCare reported that an estimated 970 million people worldwide have a mental-health or substance-abuse disorder, with anxiety being the most common mental illness in the world, impacting 284 million people. Other significant mental-health challenges that are leading causes of serious disabilities include major depression, anxiety, alcohol-use disorders, schizophrenia, bipolar disorder, and dysthymia, or persistent mild depression. Cybin has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. Most recently the company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance. “Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Doug Drysdale, Chief Executive Officer of Cybin. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” continued Drysdale. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.” The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset facilitates this; the system is equipped with hi-tech sensors that record brain activity and report a participant’s experience using structured questionnaires and validated assessments during study visits and at follow-up. Cybin and Kernel signed a partnership agreement in January 2021 that gives Cybin exclusive interest in any innovations discovered or developed through the company’s independent analysis of the study findings, while Kernel retains the same rights relating to its Kernel technology. “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Kernel founder and CEO Bryan Johnson. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help to advance these powerful new therapies for patients.” Cybin is currently working on three active drug programs: CYB003 targets major depressive disorder and alcohol use disorder, CYB004 is focused on anxiety disorders and CYB005 is studying neuroinflammation. The company has completed more than 140 preclinical studies and is making steady progress toward FDA IND filings; in addition, Cybin has developed 50 novel compounds and completed more than 10 patent filings across three patent families. The company is collaborating with a network of world-class partners and internationally recognized scientists as it progresses on its mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices
• The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug
• With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity
• CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway
• Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking incidents
• The company’s sports advisory board is headlined by NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach
• Odyssey is guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems and forging strategic partnerships

Odyssey Group International (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care. The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships. Product Portfolio Pharmaceuticals Odyssey has two pharmaceutical products in development:

• PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.

PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (“CTE”).

• PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.

Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity. Medical Devices Odyssey is also developing two medical device candidates:

• CardioMap(R) is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.

When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.

• Save-A-Life (“SAL”) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.

Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks. Market Opportunities Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%. It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach. With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028. Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications. Management Team Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University. Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University. Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY